Physician profile
John M Feild
NPI 1356390991
$1,403.32
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $122 · 2021: $395 · 2022: $66.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gemini Mountain Medical, LLC | $771.00 | 2019 | |
| Triad Life Sciences INC. | $328.47 | 2021-2022 | |
| Smith+Nephew, INC. | $98.21 | 2019-2021 | |
| Bioventus LLC | $79.52 | 2019-2021 | |
| Stryker Corporation | $29.72 | 2022 | |
| Tactile Systems Technology INC | $27.13 | 2020 | |
| Melinta Therapeutics, LLC | $18.81 | 2019 | |
| Horizon Therapeutics Plc | $17.15 | 2020 | |
| Integra Lifesciences Corporation | $16.72 | 2020 | |
| Organogenesis INC. | $16.59 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Feild listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.